December 7, 2019

Zurich, Switzerland, 4. December 2019

Chronic liver cirrhosis, mainly caused by Hepatitis B and C, has for long been a huge problem without any option for treatment. 

However, Baermed Liver Cell Technologies has developed the HMI treatment, which are "mini-livers" retrieved from a patient’s own body.  

The addressable market for the HMI treatment is calculated at over $25 billion in Asia an...

Please reload

Featured Posts

Future research in health care: Quo vadis?

August 3, 2020

Please reload

Recent Posts
Please reload

Please reload

Follow Us

Strategic Swiss Partners AG,

Bahnhofstrasse 10 / Börsenstrasse 18, 8001 Zürich  SWITZERLAND  |   +41 44 980 8000 

Copyright   ©   Strategic Swiss Partners AG 2019